Please login to the form below

Not currently logged in
Email:
Password:

arthritis

This page shows the latest arthritis news and features for those working in and with pharma, biotech and healthcare.

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

One of these potential blockbusters is JAK1 inhibitor  filgotinib, which recently reported new, long-term phase 3 clinical data in rheumatoid arthritis.

Latest news

More from news
Approximately 97 fully matching, plus 611 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that

  • NHS regional footprints NHS regional footprints

    For example, the CCG has contracted services for musculoskeletal disorders (MSK), from the Nottinghamshire Integrated Care Partnership (ICP), which is now delivering services around rheumatology, arthritis, physiotherapy, imaging, primary care

  • Nudge-nudge, think-think Nudge-nudge, think-think

    Entertainment is a great way of stimulating behaviour change.”. A good example of this is the OuchieBand campaign for Junior Idiopathic Arthritis (JIA), where we combined convenience with entertainment.

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 9 fully matching, plus 30 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics